Advertisement

Volume 1, Issue 25

 

Cover Image

Cover Figure:  Buccal epithelial cells harboring a sporadic myeloproliferative neoplasm–associated CALR mutation.
See the article by Gilles et al.

WASHINGTON, November 28,  2017 – Welcome to the “Advance Notice,”  newsletter which provides highlights from issues of Blood Advances, the open-access journal of the American Society of Hematology (ASH), that  are hand-picked by Blood Advances Editor-in-Chief Robert Negrin, MD.

This issue’s Point-Counterpoint explores the question, “What should be the goal of therapy for Waldenström macroglobulinemia?” Kastritis and Dimopoulos argue for disease control, while Treon and Castillo argue in favor of disease eradication, especially for patients with more aggressive disease. We hope you enjoy reading this discussion from experts in the field.

 

Maintenance of telomere length is a critically important biological process in health, and the role of telomere length in diseases such as acute myeloid leukemia is of great interest. In this issue, Peter M. Lansdorp, an expert in this area, discusses this topic in depth.

 

Despite the successes of allogeneic transplantation in preventing disease relapse as compared to more conventional therapies, disease recurrence is still a possibility. In a review, Soiffer and Chen systematically discuss this problem, highlighting the different pharmacological strategies available to prevent or treat this devastating clinical event.

 

The goal of a vaccine generation for HIV remains hopeful yet elusive. In addition to HIV antigens, the choice of adjuvant may have a significant impact on immune reactivity towards vaccination strategies. Francica et al tested a number of different adjuvants in nonhuman primates exposed to gp140 HIV envelope protein. Their findings may have important implications for the construction of more effective vaccine strategies.

 

The recent approval of 2 chimeric antigen receptor (CAR)–based immunotherapies is a major advance in the treatment of B-cell malignancies such as CD19+ acute lymphoblastic leukemia and B-cell lymphomas. However, to date, strategies to treat T-cell diseases have lagged. Png and colleagues describe a novel approach to target CD7 and potentially overcome this barrier.

 

Jonsdottir and colleagues evaluate the role of prior or subsequent malignancies on the survival of patients with multiple myeloma in a large population of Swedish patients. This study highlights the potential role of genetic susceptibility in the subsequent risk of other cancers.

 

 

Patients with chronic lymphocytic leukemia (CLL) can have a variable prognosis. Ahn and colleagues evaluated the impact of early disease progression, defined as progression within 2 years of initial therapy, in a cohort of 829 patients with CLL. Early disease progression was found to be a potent predictor for subsequent overall survival.

 

Primary immune thrombocytopenia (ITP) can be a challenging disease to accurately diagnose. Arnold and colleagues evaluated the frequency of ITP misdiagnosis through the analysis of the McMaster ITP Registry with interesting and surprising findings.

 

Recent evidence has pointed to the microbiome as a critical component of the risk of complex biological processes such as graft-versus-host disease as well as other outcomes following allogeneic hematopoietic cell transplantation. In a Commentary, Shono and van den Brink discuss the use of empiric antibiotics and anaerobic coverage in light of these recent findings.

 


Featured Visual Abstract

CD86 regulates myeloma cell survival

Significant progress has been made in the treatment of patients with multiple myeloma. However, a cure remains elusive. Gavile et al explored the role of the CD28-CD86 pathway and found that CD86 mediates myeloma cell survival. This study provides further evidence for therapeutic targeting of this interaction in the clinic.

 

 

 

Blood Advances is the open-access journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.